Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site

The glucagon-like peptide-1 receptor (GLP-1R) is a well-established drug target for the treatment of type II diabetes. The development of small-molecule positive allosteric modulators (PAMs) of GLP-1R is a promising therapeutic strategy. Here, we report the discovery and characterization of PAMs with distinct chemotypes, binding to a cryptic pocket formed by the cytoplasmic half of TM3, TM5, and TM6. Molecular dynamic simulations and mutagenesis studies indicate that the PAM enlarges the orthosteric pocket to facilitate GLP-1 binding. Further signaling assays characterized their probe-dependent signaling profiles. Our findings provide mechanistic insights into fine-tuning GLP-1R via this allosteric pocket and open up new avenues to design small-molecule drugs for class B G-protein-coupled receptors.

Automated summary

The study discovered small-molecule positive allosteric modulators (PAMs) of GLP-1R with distinct chemotypes that bind to a cryptic pocket formed by TM3, TM5, and TM6. Molecular dynamic simulations and mutagenesis studies revealed that PAMs enlarge the orthosteric pocket to facilitate GLP-1 binding. Further signaling assays characterized their probe-dependent signaling profiles, providing insights into fine-tuning GLP-1R via this allosteric pocket.